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Introduction: Influenza A(H3N2) viruses predominated in Europe in 2016–17. In 2017–18 A(H3N2) and A
(H1N1)pdm09 viruses co-circulated. The A(H3N2) vaccine component was the same in both seasons;
while the A(H1N1)pdm09 component changed in 2017–18. In both seasons, vaccine seed A(H3N2)
viruses developed adaptations/alterations during propagation in eggs, impacting antigenicity.
Methods: We used the test-negative design in a multicentre primary care case-control study in 12
European countries to measure 2016–17 and 2017–18 influenza vaccine effectiveness (VE) against
laboratory-confirmed influenza A(H1N1)pdm09 and A(H3N2) overall and by age group.
Results: During the 2017–18 season, the overall VE against influenza A(H1N1)pdm09 was 59% (95% CI:
47–69). Among those aged 0–14, 15–64 and 65 years, VE against A(H1N1)pdm09 was 64% (95% CI:
37–79), 50% (95% CI: 28–66) and 66% (95% CI: 42–80), respectively. Overall VE against influenza A
(H3N2) was 28% (95% CI: 17–38) in 2016–17 and 13% (95% CI: 15 to 34) in 2017–18. Among 0–14-
year-olds VE against A(H3N2) was 28% (95%CI: 10 to 53) and 29% (95% CI: 87 to 73), among 15–
64-year-olds 34% (95% CI: 18–46) and 33% (95% CI: 3 to 56) and among those aged 65 years 15%
(95% CI: 10 to 34) and 9% (95% CI: 74 to 32) in 2016–17 and 2017–18, respectively.
Conclusions: Our study suggests the new A(H1N1)pdm09 vaccine component conferred good protection
against circulating strains, while VE against A(H3N2) was <35% in 2016–17 and 2017–18. The egg prop-
agation derived antigenic mismatch of the vaccine seed virus with circulating strains may have con-
tributed to this low effectiveness. A(H3N2) seed viruses for vaccines in subsequent seasons may be
subject to the same adaptations; in years with lower than expected VE, recommendations of preventive
measures other than vaccination should be given in a timely manner.
 2019 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
WHO recommended the same influenza A(H3N2) Northern
Hemisphere vaccine component for the 2016–17 and 2017–18 influ-
enza seasons: A/Hong Kong/4801/2014 (H3N2)-like virus. An A/Cal-
ifornia/7/2009 (H1N1)pdm09-like virus vaccine component was
recommended for the seventh consecutive year in the 2016–17 sea-
son. This was replaced with an A/Michigan/45/2015 (H1N1)pdm09-
like virus vaccine component in the 2017–18 season.
Influenza A(H3N2) was the predominant circulating influenza
virus in Europe in the 2016–17 season with very little A(H1N1)
pdm09 and B circulating [1,2]. While overall in Europe in the
2017–18 season influenza B/Yamagata virus lineage-mismatched
to the trivalent vaccine was the main circulating strain, both A
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particularly among the elderly, in 2016–17 coinciding with a pre-
dominance of A(H3N2) [3,4].
Since 2008–9, the I-MOVE/I-MOVE+ (Influenza Monitoring Vac-
cine Effectiveness in Europe) primary care multicentre case control
study (MCCS) has provided vaccine effectiveness (VE) estimates by
influenza virus (sub)type, age group, and target population. Since
2012–13, VE has also been estimated by vaccine type, and since
2015–16, by virus genetic clade [5–7].
We present the I-MOVE/I-MOVE+MCCS VE estimates against
influenza A by subtype for the 2016–17 and 2017–18 seasons.
We estimate VE by age group (including birth cohorts who may
be more susceptible for infection [8]), target population, previous
vaccination, vaccine type, time within the season and also estimate
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elsewhere in context of VE against influenza B in post-pandemic
seasons.2. Methods
Eleven European study sites (in Croatia, France, Germany, Ire-
land, Italy, Poland, Portugal, Romania, Spain, Sweden and the
Netherlands) participated in our 2016–17 and 2017–18 I-MOVE/
I-MOVE+MCCS, while one (in Hungary) participated in the in the
2016–17 MCCS only. Each study site used the test-negative design
using the European Centre for Disease Prevention and Control
(ECDC) generic case-control study protocol and the I-MOVE
+protocol [9,10]. The methods are described in detail elsewhere
[5,11].
Briefly, for each season, participating practitioners interviewed
and collected nasopharyngeal or combined naso- and oro-
pharyngeal specimens from a systematic sample of consenting
patients seeking medical attention for influenza-like illness (ILI).
Practitioners collected information including symptoms, date of
onset and swabbing, current seasonal influenza vaccination status,
date of influenza vaccination and vaccine product, seasonal influ-
enza vaccination status from the previous season, sex, age and
presence of chronic medical conditions in the past 12 months.
In the pooled analysis we included patients meeting the Euro-
pean Union ILI case definition [12], swabbed within 7 days of
symptom onset, and who had not received antivirals in the 14 days
prior to swabbing. Study sites with fewer than 10 influenza-
positive cases by influenza subtype or with fewer than 10 vacci-
nated patients were excluded from the pooled analysis.
A case of confirmed influenza was an ILI patient who had been
swabbed and whose test result was positive for influenza A virus
using real-time, reverse-transcription polymerase chain reaction
(RT-PCR). Controls were ILI patients who tested negative for any
influenza virus using RT-PCR.
We defined a person as vaccinated if they had received at least
one dose of current seasonal influenza vaccine more than 14 days
before ILI symptom onset. Those vaccinated fewer than 15 days
before ILI onset were excluded. All other patients were classified
as unvaccinated.2.1. Statistical methods
We conducted a complete case analysis, in which patients with
missing values for any of the variables in the model measuring
adjusted VE are excluded. We computed the pooled VE for each
influenza A subtype as (1-OR) * 100 using a one-stage logistic
regression model with study site as a fixed effect.
We calculated VE adjusting for a priori confounding factors:
symptom onset date, age, sex, and presence of at least one chronic
disease or other risk conditions such as pregnancy and obesity
(where available). The continuous variables symptom onset date
and age in years were modelled as restricted cubic splines with
3, 4 or 5 knots, or as categorical variables (age group, onset month
or onset week), the choice of which was determined by sample size
and the Akaike information criterion. We used the ‘‘one in ten” rule
of covariate degrees of freedom to events to determine if we were
overfitting the model [13]. If the number of events/parameters was
less than 10, we conducted a sensitivity analysis using Firth’s
method of penalised logistic regression [14].
To study the effect of prior seasonal influenza vaccination on
the current season VE, we conducted an indicator analysis using
four categories: individuals unvaccinated in both seasons (refer-
ence group), vaccinated in the previous season only, vaccinated
in the current season only, and those vaccinated in both seasons.We did not measure effect of previous vaccination among children
aged <9 years, due to their multi-seasonal vaccination schedule.
We measured VE by age group (0–14, 15–64 and 65 years and
older) and in the target group for vaccination, which includes per-
sons aged 60 or 65 years and older (depending on study site), per-
sons with underlying medical conditions and other risk groups
[15]. For the A(H1N1)pdm09 age-specific analysis among adults,
we also stratified VE by the Linderman birth cohort of heightened
susceptibility (1965–1979) due to influenza pre-exposure history,
resulting in the age groups of 15–37, 38–52, and 53 years and over
[8]. We measured VE by type of vaccine (inactivated subunit, inac-
tivated split virion and MF59 adjuvanted), including only study
sites in the analysis where vaccines of that type were available.
We measured VE by calendar time, estimating influenza A
subtype-specific VE from October to December, in January and in
February–April, in order to obtain early, peak and end of season
estimates, respectively.
Data management and statistical analyses were carried out
using Stata 15.1 [16].
2.2. Laboratory methods
Nine study sites in 2016–17 and eight in 2017–18 selected
either all influenza virus-positive specimens or a random propor-
tion of specimens for sequencing the haemagglutinin gene seg-
ment (HA) for each influenza A subtype. HA consensus sequences
were uploaded by each site to GISAID and downloaded for cen-
tralised phylogenetic and amino acid substitution analysis of the
HA1 coding portion in MEGA6 to determine clade distribution at
the National Influenza Centre, Madrid. Amino acid composition
analysis was done relative to the egg-adapted high growth reassor-
tant X-263B vaccine strain of A/Hong Kong/4801/2014 H3N2
(GISAID accession number EPI731469). For H1N1pdm09 viruses
the egg-adapted high growth reassortant X-179A vaccine strain
of A/California/07/2009 (GISAID accession number EPI257201)
and X-275A vaccine strain of A/Michigan/45/2015 (GISAID acces-
sion number EPI830230) were used as a reference for seasons
2016–17 and 2017–18, respectively.3. Results
In the 2016–17 season we included 4909 influenza A(H3N2)
cases and 6098 test-negative controls. Due to low numbers of
influenza A(H1N1)pdm09 (N = 118) and B (N = 190) cases, no VE
analysis against these was attempted (Fig. 1).
In the 2017–18 season, we included 1958 influenza A(H1N1)
pdm09 cases, 756 influenza A(H3N2) cases and 5887 test-
negative controls in the I-MOVE/I-MOVE+MCCS VE analyses
(Fig. 1).
3.1. Participant profile and virological description
3.1.1. Influenza A(H3N2): 2016–17 and 2017–18
The median age of A(H3N2) cases was 32 years in 2016–17 and
41 years in 2017–18, compared to 31 and 32 years in controls in
the same seasons, respectively (Supplementary Table 1). The vac-
cine coverage among cases was 11% in 2016–17 and 16% in
2017–18, compared to 12% in controls in both seasons.
In the 2016–17 and 2017–18 influenza seasons we included
1050 and 312 sequenced A(H3N2) viruses, respectively in the
genetic analysis (Table 1). In 2016–17, 256 (24%) belonged to the
3C.2a clade represented by A/HongKong/4801/2014, 781 (74%)
belonged to the 3C.2a1 clade represented by A/Singapore/INFIM
H-16–0019/2016 (in 2016–17 the representative virus for this
clade was A/Bolzano/7/2016, however we use the 2017–18
Fig. 1. Number of ILI patients by case status (test negative controls and cases by influenza (sub)type) and week of symptom onset, I-MOVE/I-MOVE+ primary care multicenter
case control study, Europe, influenza seasons 2016–17 and 2017–18. ILI: Influenza-like illness; ISO: International Organization for Standardization.
4 E. Kissling et al. / Vaccine: X 3 (2019) 100042representative virus for easier comparison between seasons) and
13 (1%) belonged to the 3C.3a clade represented by A/Switzer-
land/9715293/2013. In 2017–18, 173 (55%) belonged to the 3C.2a
clade, 134 (43%) belonged to the 3C.2a1 clade and 5 (2%) belonged
to the 3C.3a clade.
In 2016–17 there was a variety of amino acid substitutions in
antigenic sites within the 3C.2a and 3C.2a1 clades in most studies,
the proportion of which varied between countries (Table 1).
Conversely, in 2017–18, 167/173 (97%) of the viruses of the A/
HongKong/4801/2014 3C.2a clade belonged to the 3C.2a2 subclade
with the T131K, R142K and R261Q amino acid substitutions rela-
tive to the vaccine strain A/HongKong/4801/2014. Among the
134 viruses in 2017–18 belonging to the A/Singapore/INFIMH-
16-0019/2016 3C.2a1 clade, 132 (99%) belonged to the 3C.2a1b
subclade with the N171K, N121K, K92R and H311Q amino acid
substitutions relative to the vaccine strain A/
HongKong/4801/2014.3.1.2. Influenza A(H1N1)pdm09: 2017–18
The median age of influenza A(H1N1)pdm09 cases was
19 years, compared to 32 years for influenza test-negative controls
(Supplementary Table 1). Among A(H1N1)pdm09 cases, 47%
belonged to the 0–14 years age group, compared to 33% of controls.
The vaccination coverage was 4% among A(H1N1)pdm09 cases,
compared to 12% among controls.
All A(H1N1)pdm09 sequenced viruses belonged to the clade
represented by the A/Michigan/45/2015 vaccine virus (clade
6B.1) (Table 1).3.1.3. Vaccines used in 2016–17 and 2017–18
In both seasons, all vaccines used were egg-propagated. Among
vaccinated controls with known vaccine brand in 2016–17
(572/685, 84%), 100 (17%) received adjuvanted vaccine, 52 with
aluminium phosphate gel and 48 with MF59 adjuvant, and nine
(2%) received a live attenuated influenza vaccine (LAIV) (Supple-
mentary table 1). Among vaccinated controls with known vaccine
brand in 2017–18 (556/687, 81%), 30 (5%) received adjuvanted vac-
cine, all with MF59 adjuvant, and eight vaccinated participants
(1%) received LAIV. In 2016–17 and 2017–18, 79% and 84% of vac-
cines with known brand were inactivated non-adjuvanted trivalent
vaccines.3.2. 2016–17 and 2017–18 vaccine effectiveness estimates against A
(H3N2)
3.2.1. Overall
The VE against influenza A(H3N2) among all ages in 2016–17
was 28% (95% CI: 17–38) and in 2017–18 13% (95% CI: 15 to
34) (Table 2). Among all ages in the target group for vaccination
the VE was 22% (95% CI: 7–34) in 2016–17 and 13% (95% CI: 21
to 38) in 2017–183.2.2. By age group
The VE against A(H3N2) in 2016–17 was 28% (95% CI: 10 to
53), 34% (95% CI: 18–46) and 15% (95% CI 10 to 34) among those
aged 0–14, 15–64 and 65 years, respectively.
The VE against influenza A(H3N2) in 2017–18 was 29% (95% CI:
87 to 73), 33% (95% CI: 3 to 56) and 9% (-74 to 32) among
those aged 0–14, 15–64 and 65 years, respectively.3.2.3. VE by clade/subclade
The VE in 2016–17 against all variants of 3C.2a excluding
3C.3a1 was 31% (95% CI: 12 to 57) and the VE against the
3C.2a3 subclade was 37% (95% CI: 9 to 63) (Table 3). In 2016–
17 the VE against all 3C.2a1 variants was 25% (95% CI: 1 to 44).
The VE against 3C.2a1 with no mutations in A-E antigenic sites
except for N171K was 56% (95% CI: 20–76). The VE against the
3C.2a1b subclade was 7% (95% CI: 56 to 45).
In 2017–18 the VE against all variants of 3C.2a excluding 3C.3a1
was 29% (109 to 21). The vast majority (160/166) of 3C.2a
viruses belonged to the subclade 3C.2a2, against which the VE
was 19 (95% CI: 95 to 27). The VE against 3C.2a1b was 43%
(95% CI: 16 to 72).3.2.4. By vaccine group
In 2016–17, among all ages, the VE of the trivalent subunit vac-
cine against A(H3N2) was 31% (95% CI: 13–46) and of the trivalent
split virion vaccine was 23% (95% CI: 4–39). The VE of the MF59
adjuvanted trivalent subunit vaccine, used in three study sites,
against A(H3N2) was 49% (95% CI: 12–71).
In 2017–18, the VE of the trivalent subunit vaccine against A
(H3N2) was 3% (95% CI: 50 to 30) and the VE of the trivalent
split virion vaccine against A(H3N2) was 19 (95% CI: 29 to 49).
Table 1
Genetic group distribution among nine study sites participating in the random sequencing of influenza virus positive specimens. I-MOVE/I-MOVE+ primary care multicenter case control study, Europe, influenza season 2016–17 and
2017–18.
Characterised viruses1 Clade/subclade DE ES FR HU IE NL PT RO SE Total
N % N % N % N % N % N % N % N % N % N %
2016–17 A(H3N2) 207 346 87 51 63 80 124 25 67 1050
A/HongKong/4801/2014-like 3C.2a 47 23 59 17 28 32 15 29 14 22 16 20 42 34 10 40 25 37 256 24
* 1 2 0 0 0 0 0 0 0 0 2 13 2 5 0 0 0 0 5 2
N121K+S144K+(N122D+262N) 3C.2a3 30 64 54 92 27 96 14 93 11 79 8 50 38 90 10 100 16 64 208 81
T131K+R142K+R261Q 3C.2a2 16 34 5 8 1 4 1 7 3 21 6 38 2 5 0 0 9 36 43 17
A/Bolzano/7/2016-like2 3C.2a1 159 77 280 81 59 68 36 71 45 71 63 79 82 66 15 60 42 63 781 74
N171K 14 9 137 49 40 68 1 3 1 2 9 14 1 1 6 40 7 17 216 28
N171K+N121K+I140M – 32 20 58 21 7 12 2 5 6 13 14 22 6 7 7 47 8 19 140 18
N171K+N121K+K92R+H311Q 3C.2a1b 43 27 59 21 1 2 4 11 5 11 18 29 29 35 1 7 1 2 161 21
N171K+N121K+T135K 3C.2a1a 54 34 8 3 2 3 28 78 1 2 11 17 0 0 1 7 22 52 128 16
N171K+R142G – 16 10 18 6 9 15 1 3 32 71 11 17 46 56 0 0 4 10 137 18
A/Switzerland/9715293/2013-like 3C.3a 1 0 7 2 0 0 0 0 4 6 1 1 0 0 0 0 0 0 13 1
Characterised viruses Clade/subclade DE ES FR HU IE NL PT RO3 SE Total
N % N % N % N % N % N % N % N % N % N %
2017–18 A(H1N1)pdm09 43 10 64 – 13 31 22 13 9 205
A/Michigan/45/2015-like 6B.1 43 100 10 100 64 100 13 100 31 100 22 100 13 100 9 100 205 100
A(H3N2) 25 141 35 – 48 26 13 – 24 312
74A/HongKong/4801/2014-like 3C.2a 23 92 44 31 25 71 – 41 85 18 69 7 54 – 15 63 173 55
* 0 0 0 0 0 0 – 0 0 0 0 0 0 – 0 0 0 0
N121K+S144K+(N122D+262N) 3C.2a3 2 9 0 0 1 4 – 3 7 0 0 0 0 – 0 0 6 3
T131K+R142K+R261Q 3C.2a2 21 91 44 100 24 96 – 38 93 18 100 7 100 – 15 100 167 97
A/Singapore/INFIMH-16-0019/2016-like2 3C.2a1 2 8 97 69 8 23 – 6 13 8 0 6 46 – 7 29 134 43
N171K+N121K 0 0 0 0 0 0 – 0 0 0 0 0 0 – 0 0 0 0
N171K+N121K+I140M – 0 0 0 0 0 0 – 0 0 0 0 0 0 – 0 0 0 0
N171K+N121K+K92R+H311Q 3C.2a1b 1 50 96 99 8 100 – 6 100 8 100 6 100 – 7 100 132 99
N171K+N121K+T135K 3C.2a1a 1 50 1 1 0 0 – 0 0 0 0 0 0 – 0 0 2 1
N171K+R142G – 0 0 0 0 0 0 – 0 0 0 0 0 0 – 0 0 0 0
A/Switzerland/9715293/2013-like 3C.3a 0 0 0 0 2 6 – 1 2 0 0 0 0 0 2 8 5 2
Total 2017–18 68 151 89 – 61 57 35 13 33 517
* Viruses with no amino acid substitutions or substitutions outside of the A–E antigenic sites.
1 We use for both seasons the clade/subclade denomination created in mid-season in 2017-18 (report prepared by the Francis Crick Institute for the WHO annual consultation on the composition of influenza vaccine for the
Northern Hemisphere 2018-2019). Therefore some clades/subclades circulating in 2016–17, but not in 2017–18, have no specific clade/subclade denomination. All amino acid substitutions shown for the A(H3N2) overarching
clade 3C.2a viruses are relative to the vaccine virus A/HongKong/4801/2014.
2 A/Bolzano/7/2016 and A/Singapore/INFIMH-16-0019/2016 are two representative viruses of the same clade 3C.2a1, carrying the N171K substitution in the HA gene compared to the vaccine virus A/HongKong/4801/2014. In
2016–117, A/Bolzano/7/2016 was used as the representative virus and in 2017–118 A/Singapore/INFIMH-16-0019/2016 was used being representative for clade 3C.2a1 viruses carrying N121K in addition to N171K and chosen as
vaccine strain for the 2018 Southern Hemisphere and 2018/2019 Northern Hemisphere vaccines.












Pooled adjusted seasonal vaccine effectiveness against influenza A(H1N1)pdm09 and A(H3N2), overall, by age groups and by vaccine type, previous vaccination and time within
the season. I-MOVE/I-MOVE+ primary care multicenter study, Europe, influenza seasons 2016–17 and 2017–18.
Influenza A(H3N2) 2016–17
Age group Population Na Cases; vacc /Controls; vaccb Adjusted VE (%) 95% CI (%)
All ages 10,591 4733;516/5858;680 28 17–38
0–14 years 3452 1494;46/1958;66 28 10 to 53
15–64 years 5840 2606;183/3234;286 34 18–46
65 years 1298 633;287/665;328 15 10 to 34
All ages Target group for vaccination 3181 1440;431/1741;543 22 7–34
All ages Subunit vaccinea 8304 3832;179/4472;238 31 13–46
Split virion vaccinea 9303 4209;188/5094;220 23 4–39
Adjuvanted vaccinea 4678 2027;32/2651;48 49 12–71
9 years Unvaccinated 7822 3168/3343b Ref
2016–17 vaccine only 69/132b 50 32–63
2015–16 vaccine only 87/144b 29 5–47
2015–16 and 2016–17 vaccines 412/467b 20 5–32
All ages Oct-Dec 3541 1442;141/2099;206 38 16–54
Jan 4379 2389;260/1990;289 34 18–47
Feb-April 2671 902;115/1769;185 1 34 to 27
Influenza A(H3N2) 2017–18
Age group Population N Cases; vacc /Controls; vacc Adjusted VE (%) CI (%)
All ages 5607 731;119/4876;623 13 15 to 34
0–14 years 1772 160;6/1612;74 29 87 to 73
15–64 years 3128 444;33/2684;245 33 3 to 56
65 years 673 127;80/546;283 9 74 to 32
All ages Target group 1763 251;106/1512;512 13 21 to 38
All ages Subunit vaccine a 4556 471;56/3739;290 3 50 to 30
Split virion vaccine a 4637 555;36/3906;140 19 29 to 49
9 years Unvaccinated 4051 491/2783b
17–18 vaccine only 11/105b 49 1–74
16–17 vaccine only 17/119b 16 47 to 52
16–17 and 17–18 vaccines 95/430b 7 29 to 33
All ages Oct-Dec 1413 138;19/1275;133 11 72 to 54
Jan 1849 230;42/1619;234 5 54 to 41
Feb-April 2345 363;58/1982;256 18 24 to 45
Influenza A(H1N1)pdm09 2017–18
Age group Population N Cases; vacc /Controls; vacc Adjusted VE (%) CI (%)
All ages 7175 1875;81/5300;643 59 47–69
0–14 years 2680 888;18/1792;80 64 37–79
15–64 years 3806 893;37/2913;256 50 28–66
65 years 684 94;26/590;307 66 42–80
15–37 years 1609 339;4/1270;54 71 18 to 90
38–52 years 1311 369;18/942;70 23 38 to 57
53+years 1572 279;41/1293;439 64 47 to 76
All ages Target group 2075 424;65/1651;526 56 40–68
All ages Subunit vaccine a 6268 1745;39/4192;292 59 40–71
Split virion vaccine a 6184 1745;11/4288;140 71 45–85
9 years Unvaccinated 4784 981/3023b
17–18 vaccine only 6/110b 79 51–91
16–17 vaccine only 25/137b 24 22 to 52
16–17 and 17–18 vaccines 61/441b 46 26–61
All ages Oct-Dec 2009 326;4/1683;152 87 62–95
Jan 2277 673;33/1604;230 53 27–69
Feb-April 2826 856;44/1970;257 53 32–67
CI: confidence interval; vacc: vaccinated; VE: vaccine effectiveness.
a Among study sites where this vaccine type was used. Subunit and split virion vaccine refers to egg-propagated inactivated trivalent subunit and split virion vaccines,
respectively. For adjuvanted vaccine only study sites using the MF59 adjuvant included.
b Cases/controls.
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In 2016–17, using those unvaccinated in current and prior sea-
son as a reference group, the VE among those aged 9 years was
50% (95% CI: 32–63) in those vaccinated in the current season only,
20% (95% CI: 5–32) in those vaccinated in both seasons, and 29%
(95% CI: 5–47) in those vaccinated in previous season only.
In 2017–18, using those unvaccinated in current and prior sea-
son as a reference group, the VE among those aged 9 years was49% (95% CI: 1–74) in those vaccinated in the current season only,
7% (95% CI: 29 to 33) in those vaccinated in both seasons and 16%
(95% CI: 47 to 52) in those vaccinated in previous season only.
3.2.6. By calendar time
In 2016–17 the VE was 38% (95% CI: 16–54) in October to
December, 34% (95% CI: 18–47) in January and 1% (95% CI: 34
to 27) in February to April among all ages.
Table 3
Pooled adjusted seasonal vaccine effectiveness against influenza A(H3N2) clades and subclades, I-MOVE/I-MOVE+ primary care multicenter study, Europe, influenza seasons
2016–17 and 2017–18.
Season Clade/subclade N Cases; vacc /Controls; vacc Adjusted VE (%) CI (%)
2016–17 3C.2a (all variants excluding 3C.2a1) 4492 252;28/4240;496 31 12 to 57
3C.2a3
N121K+S144K+(N122D+262 N)
4445 205;20/4240;496 37 9 to 63
3C.2a1 (all variants) 5007 767;99/4240;496 25 1 to 44
3C.2a1 (no mutations in A-E antigenic sites other than N171K) 4454 214;19/4240;496 56 20 to 76
3C.2a1b
N171K+N121K+K92R+H311Q
4397 157;30/4240;496 7 56 to 45
2017–18 3C.2a (all variants) 3732 166;40/3566;445 29 109 to 21
3C.2a2
T131K+R142K+R261Q
3726 160;38/3566;445 19 95 to 27
3C.2a1 (all variants) 3698 132;17/3566;445 41 19 to 71
3C.2a1b
N171K+N121K+K92R+H311Q
3697 131;17/3566;445 42 18 to 71
CI: confidence interval; vacc: vaccinated; VE: vaccine effectiveness.
E. Kissling et al. / Vaccine: X 3 (2019) 100042 7In 2017–18 the VE was 11% (95% CI: 72 to 54), 5% (95% CI: 54
to 41) and 18% (95% CI:24 to 45) in October to December, January
and in February to April among all ages, respectively.3.3. 2017–18 vaccine effectiveness estimates against A(H1N1)pdm09
3.3.1. Overall and by age group
In the 2017–18, 1875 A(H1N1)pdm09 cases and 5300 test-
negative controls were included in the complete case VE analysis.
The overall VE was 59% (95% CI: 47–69). Among the target group
for vaccination (N = 2075) the VE was 56% (95% CI: 42–68)
(Table 2).
The VE was 64% (95% CI: 37–79), 50% (95% CI: 28–66%) and 66%
(95% CI 42–80) among patients aged 0–14, 15–64 and 64 years,
respectively.
The VE among those aged 15–37 years was 71% (95% CI: 18–90),
among those aged 38–52 years (corresponding to the Linderman
birth cohort of susceptibility of 1965–79) 23% (95% CI: 38 to
57) and among those aged 53 and over 64% (95% CI: 47–76).3.3.2. By vaccine type
VE was 59% (95%CI: 40–71) for the trivalent inactivated subunit
vaccine and 71% (95% CI: 45–85) for the trivalent inactivated split
virion vaccine. Numbers were too low to estimate VE for the MF59
adjuvanted vaccine.3.3.3. By previous vaccination
In the 9 years olds (N = 4784), compared to those receiving no
vaccine in current or prior season, the VE was 79% (95% CI: 51–91)
among those receiving the 2017–18 vaccine only and 46% (95% CI:
26–61) among those receiving both 2016–17 and 2017–18 vaccine.3.3.4. By calendar time
VE was 87% (95% CI: 62–95) in October to December, 53% (95%
CI: 27–69) in January and 53% (95% CI: 32–67%) in February to
April (see Table 2).4. Discussion
In 2017–18 the influenza VE against primary care medically
attended ILI due to influenza A(H1N1)pmd09 in the I-MOVE/I-
MOVE+MCCS in Europe was 56 and 59% in the total and target pop-
ulation, respectively. The VE against A(H3N2) in 2016–17 was 22%
and 28% in the total and target populations, respectively, and in
2017–18 it was 13% in both populations.4.1. Influenza A(H1N1)pdm09
The 2017–18 season was the first season of the new A/
Michigan/45/2015-like virus vaccine component after seven con-
secutive seasons of the A/California/7/2009 (H1N1)-like virus vac-
cine component. The A/California/7/2009 (H1N1)-like virus was
maintained from 2010-11 to 2016–17 in the Northern Hemisphere
vaccine. Despite evolution of the A(H1N1)pdm09 viruses into dis-
tinct genetic clades there were was no significant antigenic drift,
making a vaccine strain switch unnecessary until recently. Clades
6B and 6C started to circulate in Europe in 2012–13. From 2014
to 15 onwards, all genetically characterised viruses reported to
ECDC belonged to genetic subgroup 6B, characterised by a K163Q
substitution in HA1 [17,18]. In 2015–16, 90% (652/723) of all sys-
tematically selected A(H1N1)pdm09 viruses characterised in the
I-MOVE/I-MOVE+MCCS belonged to the 6B.1 subgroup, defined
by the S84N, I216T and S162N substitutions. This latter substitu-
tion may result in a potential new glycosylation site [6]. These
recent genetic clades were antigenically distinct when using
human antisera following vaccination [1,18]. This was also
reflected in the 2015–16 VE against A(H1N1)pdm09 of 33% (95%
CI: 4 to 57) among all ages in the I-MOVE/I-MOVE+MCCS, which
was lower than previous seasons. This decline in VE across seasons
was also seen in Canada, but not in the UK [6,7,15,19–21]. The I-
MOVE/I-MOVE+MCCS 2017–18 season VE of 59% (95% CI: 47–69)
indicates that the vaccine component change was successful,
underlining the importance of complementation of antigenic char-
acterisation of viruses using naïve ferret antisera with antisera
derived from vaccinated humans from different age groups [22].
The process of ‘‘original antigenic sin” is where human antibody
responses cross-react to influenza strains experienced in early
childhood when challenged by a newer viral strain [23]. In 2014,
Linderman et al. proposed that this process explained a heightened
susceptibility to the circulating A(H1N1)pdm09 6B clade in some
birth cohorts. These people may have experienced childhood expo-
sure to A(H1N1) viruses with the K163 epitope, not the case in
younger adults whose childhood exposure was to A(H1N1) viruses
with this epitope masked [8]. Linderman et al. reported that partic-
ular birth cohorts 1965 to 1979 had K163-specific antibodies in
their sera. They therefore recommended a change in vaccine from
the A/California/7/2009 (H1N1)-like virus, whilst indicating never-
theless the uncertainty that a vaccine change will break the ‘‘orig-
inal antigenic sin”. The VE against A(H1N1)pdm09 among the
1965–1979 birth cohort (38–52 years) in the 2017–18 I-MOVE/I-
MOVE+MCCS was 22%, lower than among other age groups. This
VE against A(H1N1)pdm09 is similar to the VE reported in 2015–
16 in the US among similar birth cohorts (VE = 23%) [24]. The dip
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apparent in the 2015–16 I-MOVE/I-MOVE+MCCS, where VE was
low overall [6,20]. The age-specific VE we observe in the our study
in the 2017–18 season may be due to random variation, or due to a
more complex interplay of influenza virus exposure and vaccina-
tions [20]. Monitoring age-specific effects is warranted to better
understand susceptible populations in future influenza seasons.
Our interim VE results against A(H1N1)pdm09 were higher at
68%, with data from the start of the 2017–18 season up to the
26th of January 2018 than these end of season results (VE = 59%)
[25]. Indeed, the VE in October to December (87%) was higher than
the VE in January and February to April (54% and 53%). A decline in
VE against A(H1N1)pdm09 by time since vaccination was also seen
in the I-MOVE/I-MOVE+MCCS in 2015-16 and a decline in VE
against A(H1N1)pdm09 by calendar time was seen in Canada in
2015-16 [20], but not in the I-MOVE MCCS between 2010 and 11
and 2014-15 [26]. While monitoring declining vaccine effect
against the 6B.1 clade warrants further research, the decline by cal-
endar time could possibly be a statistical artefact of the study.
However, the decline was not seen in VE against A(H3N2) in
2017–18, indicating that this may be at least in part a real rather
than an artefactual phenomenon for influenza A(H1N1)pdm09.
Vaccine coverage was low and numbers were small for esti-
mates of vaccine type specific VE and indicated no real difference
between VE of inactivated trivalent subunit and split virion vaccine
among all ages, similar to the I-MOVE/I-MOVE+MCCS results from
the 2013-14, 2014-15 and 2015-16 seasons [6,15,19]. Numbers for
quadrivalent and adjuvanted vaccine types were too low to esti-
mate vaccine type-specific VE.
VE among those receiving both current and prior season influ-
enza vaccine was lower than among those receiving current season
only vaccination (46% vs.79%), compared to a reference group of
those not receiving vaccine in either season. A similar pattern for
A(H1N1)pdm09, albeit with low precision, was seen in the 2015-
16 season in the I-MOVE/I-MOVE+MCCS study and also in Canada,
but not in the US [6,20,27]. The findings in the 2017–18 season
may be explained by negative interference of the prior vaccine
strain, but should be seen also in context of different profiles
among unvaccinated, single season vaccinees, vaccinated and
repeat vaccinated participants, as well as in the context of the
influence of different antibody landscapes among individuals.
4.2. Influenza A(H3N2)
Similar clades of A(H3N2) were circulating in the 2016–17 and
2017–18 influenza seasons, albeit in different proportions and with
some differing subclades, with the same vaccine component in both
seasons. VE was approximately 30% among those aged <65 years in
both seasons, and lower among those aged 65 and older.
A(H3N2) vaccine seed viruses can develop adaptations/alter-
ations during propagation in eggs, impacting antigenicity, which
may negatively affect VE [28–30]. Egg-propagated A/Hon-
gKong/4801/2014 (H3N2)-like seed vaccine viruses have the egg
adaptation induced T160K substitution, whereas 160T is present
in the original A/HongKong/4801/2014 virus and current circulat-
ing 3C.2a viruses. Viruses with 160T grow poorly in eggs, and the
T160K egg adaptation results in the loss of a putative N-
glycosylation site in the HA antigenic site B [31]. In the I-MOVE/
I-MOVE+MCCS 98-99% of all systematically sequenced A(H3N2)
viruses had 160T. These changes due to egg-adaptation may con-
tribute to the low VE observed in the 2016–17 and 2017–18 sea-
sons in our study. The A/Singapore/INFIMH-16-0019/2016
(H3N2)-like vaccine component for the Southern Hemisphere
2018 and the Northern Hemisphere 2018-19 influenza season, is
also subject to the same problems during egg adaptation in the
vaccine manufacturing process in the same critical antigenic site:vaccine seed strains having 160 K instead of 160T in the original
virus. If similar genetic variants of A(H3N2) with 160T are circulat-
ing in the future we may expect VE to be similar to the 2016–17
and 2017–18 seasons, making recommendations for other preven-
tive measures already at start of the season vital. This may be par-
ticularly crucial for older age groups, where A(H3N2) can also
cause severe disease, as younger age groups had a higher VE com-
pared to those 65 years of age and older. That said, WHO reported
that A(H3N2) strains circulating in the 2017–18 season were more
similar in HA assays to the egg-propagated A/Singapore/INFIMH-
16-0019/2016 (H3N2)-like virus (the recommended 2018-19
Northern hemisphere A(H3N2) vaccine virus component) than
the 2017–18 egg-propagated A/HongKong/4801/2014 (H3N2)-
like virus vaccine strain [32]; however early results from Europe
indicate that 2018-19 season VE against A(H3N2) may be low [33].
Low VE against influenza A(H3N2) may also be explained by the
genetic variation among circulating strains. In 2016–17 the VE
against 3C.2a variants, excluding 3C.2a1, was similar to the VE
against 3C.2a1 (31% vs 25%). In 2017–18, the VE against 3C.2a,
excluding 3C.2a1, of which almost all belonged to the 3C.2a2 sub-
clade, was lower than the VE against 3C.2a1 (29 vs 41%). The
same pattern of difference in 2017–18 between 3C.2a (with
3C.2a1 excluded) and 3C.2a1 VE was seen in other study sites
[34] [R Pebody, PHE, UK, Personal communication]. Sample size
was low, however, in particular in the 2017–18 season, and it
was not possible to disentangle age-specific and strain-specific
effects on VE. Increased sequencing of A(H3N2) viruses in seasons
with A(H3N2) circulating would help with interpretation of VE in
light of genetic changes.
There was no statistical difference between VE of inactivated
trivalent subunit and split virion vaccine in any of the age groups
in 2016–17 or in 2017–18, as in the previous A(H3N2) season in
2014-15 [19].
The 2015-16 influenza A(H3N2) vaccine component was A/
Switzerland/9715293/2013, which has 160 K in the original and
egg-adapted strains. In 2016–17 the VE among those receiving
both current and prior vaccine was lower than the VE among those
receiving current vaccine and no prior season vaccine. The pattern
was the same in 2017–18 when those receiving both current and
prior vaccine had a VE of 7% compared to the VE of 49% among
those receiving current vaccine only. The results suggest a lower
VE with combined use of current and prior vaccination, as per
the antigenic distance hypothesis [35,36]. It is possible that this
is a true phenomenon in the study, as due to passaging-related
adaptions in the vaccine virus, the antigenic distance between vac-
cine and circulating strains may be large and the vaccine viruses
are either identical (2017–18) or similar (2016–17), compared to
previous seasons. Other potential explanations include confound-
ing due to different participant profiles of repeat and single season
vaccinees, recall bias and random variation. Prospective longitudi-
nal studies are needed to better understand the phenomenon of
effects of previous vaccination.
The interim VE against A(H3N2) in 2016–17 was 38% (95% CI:
21–51)[37], higher than the end-of-season estimate of 28% (95%
CI: 17–38). When grouped into calendar months (Oct-Dec, January
and Feb-April), the 2016–17 season VE declined along the season
resulting in no effectiveness in February to April. This could be
due to virological changes in the A(H3N2) virus across the season,
waning of immunity within the individual against the vaccine, be a
statistical artefact, or a combination of all. In 2016–17, 6% (14/216)
of clade 3C.2a1 viruses with no mutations in A-E antigenic sites
other than the N171K occurred in February to April, compared to
18% (99/565) of clade 3C.2a1 viruses with mutations in the same
period (data not shown).
In 2017–18, the interim VE against A(H3N2) was 16 (95% CI:
96 to 13) compared to the 13% (-15 to 34) end-of-season estimate
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ation due to sample size and there was no evidence of change in VE
by calendar time. However, there was also less diversity of sub-
clades, so that within clade 3C.2a (excluding clade 3C.2a1) and
clade 3C.2a1, respectively, there was no consistent change in vari-
ants over time. Additionally, we may not expect any measurable
waning of immunity, with such a low overall VE (13%).
This study uses the test-negative design that has its strengths in
controlling for health care-seeking behaviour and ease of study
implementation [38]. However as with all observational studies,
we cannot rule out bias due to unmeasured confounding and selec-
tion bias. We believe these are minimised by the study design, as
the practitioners are blinded to the case status of their patients,
and to the adherence to the protocols, in which practitioners are
asked to systematically or exhaustively select patients to swab
and interview [10].5. Conclusions
Our study indicates that the new vaccine component A/Michi-
gan/45/2015 conferred greater protection to the circulating 6B.1
clade than the A/California/7/2009 vaccine strain. Receiving influ-
enza vaccine in the 2017–18 season reduced the risk of being an
A(H1N1)pdm09 case by more than half among all ages in our
study. All viruses sequenced in our study belonged to the 6B.1
clade, so we expect a similar protection of the Northern Hemi-
sphere vaccine, which contains the same A(H1N1)pdm09 strain,
against A(H1N1)pdm09, should this virus circulate in the future,
without additional common amino acid changes. To monitor this,
representative genetic and amino acid composition characterisa-
tion of circulating A(H1N1)pdm09 should complement VE studies
in coming seasons.
The VE of the A/HongKong/4801/2014 vaccine component
against A(H3N2) was <30% in the 2016–17 and 2017–18 seasons.
The circulating subclades in both seasons may have contributed
towards the low VE, as well as the amino acid substitutions within
the vaccine virus during the egg-adaption process of manufactur-
ing. No vaccines based on cell-propagated viruses were used by
participants of the 2016–17 and 2017–18 I-MOVE/I-MOVE
+MCCS. The A(H3N2) component A/Singapore/INFIMH-16-
0019/2016 recommended for the 2018-19 Northern Hemisphere
influenza vaccine is subject to the same issues of amino acid sub-
stitutions during the egg-adaption process. As influenza A(H3N2)
and A(H1N1)pdm09 co-circulated strain in the 2018-19 season, it
is possible that influenza VE against A(H3N2) will be low, particu-
larly among older adults, based on the results of our study. Excess
influenza-associated mortality and morbidity has been reported
among the elderly during previous seasons with A(H3N2) circula-
tion, when the H3N2 vaccine component showed poor or moderate
VE. Therefore, national authorities need to be prepared in such a
situation for rapid actions in reallocation of health care resources,
ensuring surge capacity and ensuring timely prescriptions and
administration of influenza antivirals.
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